Navigation Links
NeurogesX to Present at Two November Conferences
Date:10/29/2009

PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently planning the design and timing of this program.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA f
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. NeurogesX to Present at UBS Global Life Sciences Conference
2. NeurogesX to Present at Upcoming Fall Conferences
3. NeurogesX Appoints New Board Director and Audit Committee Chairman
4. NeurogesX Reports Second Quarter 2009 Results
5. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
6. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
7. NeurogesX Added to Russell 3000 Index
8. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
9. NeurogesX to Present at Needham Life Sciences Conference
10. NeurogesX Receives European Commission Approval for Qutenza(TM)
11. NeurogesX Reports First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013 Genedata, a ... biotechnology, drug discovery, and life science research, today ... ™ as its bioinformatics platform for strain ... Genedata will provide AB Enzymes, one of the ... hosted solution of Genedata Selector accompanied by bioinformatics ...
(Date:5/22/2013)... 22, 2013  Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced ... Annual Marcum LLP Microcap Conference, May 30, in ... Neil Lyons , CPA, Chief Financial Officer of Cleveland ... May 30 at 1:30 p.m. Eastern Time.  A live and ... the Investors page of the Cleveland BioLabs website at ...
(Date:5/22/2013)... 2013 AudioNotch is ... tinnitus treatment. AudioNotch is pleased to announce a ... locations in both British Columbia and Alberta, Destination ... hearing services. AudioNotch's tinnitus treatment program is now ... a Destination Hearing clinic, patients have the detection ...
(Date:5/22/2013)... Mold remediation could take a toll on ... a way to cut down the process' expense. And so, ... the details of a method how to kill mold ... be prevented, My Cleaning Products said. But in case mold ... mold remediation must then be promptly implemented as it poses ...
Breaking Biology Technology:AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2How to Kill Mold While Saving Thousands of Dollars on Mold Remediation Projects Explained by My Cleaning Products 2
... KALAMAZOO, Mich., Oct. 28 Stryker Corporation (NYSE: SYK ... District of Massachusetts has returned an indictment charging Stryker Biotech ... with wire fraud, conspiracy to defraud the U.S. Food and ... statements to the FDA. The Company disclosed in March of ...
... INCLINE VILLAGE, Nev., Oct. 28 PDL BioPharma, Inc. ... has priced a $300 million securitization transaction intended to ... , Upon closing of the transaction, which is expected ... sell to QHP Royalty Sub LLC ("QHP"), a newly-formed ...
... , GAITHERSBURG, Md., Oct. 28 GenVec, Inc. (Nasdaq: ... the third quarter ended September 30, 2009 on Thursday, November ... call at 10:00 a.m. EST on Friday, November 6, 2009 ... http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ) , To listen to ...
Cached Biology Technology:Stryker Statement in Response to the Indictment of Its Biotech Division 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 3GenVec Announces Third Quarter 2009 Results Conference Call 2
(Date:5/21/2013)... Chicago College of Medicine will study gender differences in how ... source -- and how changes in fat metabolism play a ... grant from the National Heart, Lung and Blood Institute. , ... energy. These changes may play a major role in the ... women, says E. Douglas Lewandowski, director of the UIC Center ...
(Date:5/21/2013)... Australian scientists have charted the path of insulin action ... provides a comprehensive blueprint for understanding what goes wrong ... Sean Humphrey and Professor David James from Sydney,s Garvan ... early online edition of the prestigious journal Cell ... hormone plays a very important role in the body ...
(Date:5/20/2013)... effect of physical education (PE) on child weight, but ... the amount of time that elementary schoolchildren spent in ... study represents some of the first evidence of a ... forthcoming in the Journal of Health Economics . ... be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The research ...
Breaking Biology News(10 mins):Do men's and women's hearts burn fuel differently? 2Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Gym class reduces probability of obesity, study finds for first time 2
... during pregnancy has long been a matter of concern but now ... report that even a high supplementation amount in healthy pregnant ... a level thought by some to be optimal. The study also ... highest amount, in women or their newborns. The research team, ...
... America has more than doubled in the past 10 ... greenhouses, improved cultivation technologies are essential for producers to ... facilities. Gaining popularity in greenhouse vegetable production is ... into a single stem. The system allows for uniform ...
... last 50 years have decreased dramatically. From habitat degradation ... populations and made certain species all but disappear. ... Tourism by Austin J. Gallagher and Dr. Neil ... the University of Miami study the impact of these ...
Cached Biology News:Vitamin D supplements found to be safe for healthy pregnant women 2Twin-head cucumber system reduces start-up costs 2Conservation dollars and sense 2
...
Vitellogenin (Japanese medaka) Standard...
... SAGE (serial analysis of ... genome-wide expression analysis. Expression profiles ... enough to detect low-abundance transcripts ... novel genes. The I-SAGE Kit ...
...
Biology Products: